Abstract: A method for producing a silver colloid solution of highly stable resulting colloids includes adding an aqueous solution of a hydroxylamine salt to an aqueous solution of an alkali, and then dispersing into the mixture an aqueous solution of the metal ions, the hydroxylamine salt being selected such that the anion, when combined with the said metal ions, would form a metal salt having a very low solubility in water, wherein the metal ion solution is introduced into the mixture in such a manner that the metal ions are substantially dispersed throughout the mixture within one second. A maturing period, preferably at elevated temperatures, leads to a stable state.

Abstract: Compositions which self-assemble under physiological conditions are formulated for application to wounds. The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating. The formulations may also include other therapeutic, prophylactic or diagnostic agents. The formulation can be administered as appropriate for treatment of one or more disorders or conditions. For example, the formulation may be applied to repair an injury or during surgery of the lung, eye or dura, or following an epidural or spinal tap, to stop leakage of blood, interstitial fluid, or cerebrospinal fluid.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Provided are antimicrobial solutions comprising a glyceryl nitrate (e.g., glyeryl trinitrate) in combination with a chelator (e.g., citrate), a peroxide, a fatty acid, and/or an alcohol (e.g., ethanol). In various aspects these components may synergistically act to kill or reduce the growth of microbes, such as bacteria or fungi, present in a biofilm.

Abstract: Antibodies specific for human Beclin 1 protein phosphorylated Ser234, Ser295, Tyr229, Tyr233 or Try352 are useful in diagnosing diseases such as cancer and impaired autophagy. The invention further relates to human Beclin 1 mutated at Ser234, Ser295, Tyr229, Tyr233 or Try352 with a phospho-silencing residue and uses thereof.

Abstract: A system and method for signal processing to remove unwanted noise components including: (i) wavelength-independent motion artifacts such as tissue, bone and skin effects, and (ii) wavelength-dependent motion artifact/noise components such as venous blood pulsation and movement due to various sources including muscle pump, respiratory pump and physical perturbation. Disclosed are methods, analytics, and their uses for reliable perfusion monitoring, arterial oxygen saturation monitoring, heart rate monitoring during daily activities and in hospital settings and for extraction of physiological parameters such as respiration information, hemodynamic parameters, venous capacity, and fluid responsiveness. The system and methods disclosed are extendable to include monitoring platforms for perfusion, hypoxia, arrhythmia detection, airway obstruction detection and sleep disorders including apnea.

Abstract: A method of creating biocompatible polymeric structures includes the steps of: providing a biocompatible polymer including a strained cycloalkyne end group; forming a polymeric structure from the biocompatible polymer such that the strained cycloalkyne end group remains on the biocompatible polymer; providing an azide tethered molecule; and, after forming the polymeric structure, reacting the azide tethered molecule with the cycloalkyne in an azide alkyne cycloaddition reaction to further functionalize the polymeric structure.

Abstract: A shape data generation method relating to this invention includes: first generating first three-dimensional voxel data that represents a target object by using first tomographic images, in which a first region occupied by the target object is designated, among plural tomographic images; extracting, from the first tomographic images, brightness values of voxels included in the first region; second generating a function for calculating a probability that a voxel is included in the first region by using the extracted brightness values; calculating, for each voxel among voxels in a voxel space that includes the plural tomographic images, a probability by using a brightness value of the voxel and the function; and third generating second three-dimensional voxel data that represents the target object by using the first three-dimensional voxel data and probabilities calculated for the voxels in the voxel space.

Abstract: This invention relates to representations of prostaglandin synthase three-dimensional structures. Such representations are suitable for designing agents that modulate the activity of the enzyme by binding to the substrate binding domain.

Abstract: A method of treating a patient to reduce risk of developing Clostridium difficile-associated disease or reducing existing Clostridium difficile-associated disease in a mammalian subject involves administering to a mammalian subject an effective amount of a germination-inhibiting compound derived from taurocholate. Novel compounds of this class are also provided.

Abstract: The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided for the diagnosis and treatment of arthritis.

Abstract: The present invention provides antimicrobial solutions that comprise at least one alcohol, at least one antimicrobial agent and at least one chelator and/or anticoagulant. Also provided are methods for rapidly reducing a microbe or a virus from surfaces including surfaces of indwelling medical devices and organic surfaces such as skin and sutures, and inorganic surfaces such as hospital equipment, pipelines etc.

Abstract: There are provided a novel series of peptide analogs of hGH-RH(1-29)NH2 and hGH-RH(1-30)NH2 which show high activities in stimulating the release of pituitary GH in animals. They retain their physiological activity in solution for extended periods of time and resist enzymic degradation in the body. These novel and useful properties appear to be due to novel substitution patterns ant at the 1, 15, 27 and 29 positions on the peptide.

Abstract: The present invention provides a new class of excited state intramolecular charge transfer (ESIPT) dye compounds based on mono or dihydroxy substituted 1,3-bisiminoisoindole motif and metal complexes containing such compounds as ligands. The present invention also provides OLEDs containing the compound and/or metal complex as the emissive material.

Abstract: A titanium oxide particle that can develop non-conventional and novel physical properties, a method for manufacturing the same, and a magnetic memory, an optical information recording medium, and a charge accumulation type memory using the same are provided. A silica-coated titanium hydroxide compound particle is directly produced through a sol-gel technique and not through a reverse micelle technique, and the silica-coated titanium hydroxide compound particle is subjected to a calcination process. Hence, a titanium oxide particle 1 can be provided which can develop non-conventional and novel physical properties such that it does not perform phase transition at a room temperature and a Ti3O5 particle body can always maintain the characteristic as a paramagnetic metal in all temperature ranges unlike conventional bulk bodies that perform phase transition between a non-magnetic semiconductor and a paramagnetic metal at a temperature near about 460 K.

Abstract: The invention provides transgenic Escherichia coli cells comprising a mutation in cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene, wherein the mutation reduces (preferably, but not necessarily, by 100%) the cytochrome oxydase activity of a protein encoded by cydAB gene, and/or cyoABCD gene, and/or cbdAB gene, and/or ygiN gene. In a preferred embodiment, the mutation is a deletion of the cydAB gene, cyoABCD gene, and cbdAB gene. In another embodiment, the mutation is a deletion of the cydAB gene, cyoABCD gene, cbdAB gene, and ygiN gene.

Abstract: The present invention generally relates to polyurethanes and polyurethane prepolymers having improved mechanical properties over ordinarily produced polyurethanes or polyurethane prepolymers. Such polyurethanes and prepolymers include very small amounts of organically-modified layered clays, and more specifically, less than 1 weight percent, based upon the total polymer composition, of a layered clay exfoliated with organic quaternary ammonium salts having alkyl substituents, wherein at least one of the alkyl substituents carries an —NH2 group.

Abstract: Vaccine vectors and methods for enhancing resistance to Campylobacter infection or for enhancing the immune response to Campylobacter are provided herein. The vaccine vectors include a first polynucleotide which encodes an antigenic polypeptide selected from SEQ ID NO: 7-9 or a fragment thereof. The vector may also include an immunostimulatory polypeptide. The methods include administering the vaccine vectors to a subject.

Abstract: An apparatus for presuming positions of organs is configured to transform plural organs included in a template that is a model including the plural organs so as to match a predetermined target organ among the plural organs in the template to a corresponding organ in volume data; and perform a first processing and a second processing a predetermined number of times. The first processing includes transforming a first organ selected among the plural organs in the template according to a corresponding first organ in the volume data, and the second processing includes transforming, for each of second organs that are predetermined organs, which are influenced by transformation of the first organ, the second organ according to transformation performed for third organs that are predetermined organs, which influence the second organ in the template.

Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.